I feel that Bunka was alluding to this fact many times when he expressed his reasons for uplisting. He often hinted at the difficulty of raising money while not being on a senior exchange.
Also, as the company was increasingly needing to raise more and more money to support the greater numbers of studies, patent costs, legal fees and general costs, it only makes sense that to grow the company at all they would need to uplist or risk barely scraping by or going broke, doing a few studies a year.
I believe Chris saw this as a way to get the ball rolling in a bigger way and hopefully garnering more attention at the same time. The more studies they do concurrently, the faster they'll find real partners. The old "Go big or go home" routine seems to be the plan.
Market Data 
Markets 
AI
